NASDAQ:PLRX Pliant Therapeutics Q3 2026 Earnings Results & Report $0.69 0.00 (-0.55%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$0.69 0.00 (-0.03%) As of 11/16/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pliant Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.39 versus the -$0.3703 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeAfter Market ClosesConference Call7:00 AM ET Pliant Therapeutics EPS ResultsActual EPS-$0.39Consensus EPS -$0.3703Beat/MissMissed by -$0.0197One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersPliant Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Pliant Therapeutics Q3 2026 Earnings FAQ Did Pliant Therapeutics beat earnings estimates for Q3 2026? Pliant Therapeutics (NASDAQ:PLRX) reported earnings of -$0.39 per share for Q3 2026, missing the consensus estimate of -$0.3703. The report was announced on Thursday, November 12, 2026. Pliant Therapeutics Earnings HeadlinesPliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsNovember 12, 2026 | globenewswire.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders. | Base Camp Trading (Ad)Pliant Therapeutics (NASDAQ:PLRX) versus Arbutus Biopharma (NASDAQ:ABUS) Head-To-Head ComparisonNovember 10, 2026 | americanbankingnews.comPliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of CancerNovember 9, 2026 | globenewswire.comPliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to "Sell"November 7, 2026 | americanbankingnews.comSee More Pliant Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pliant Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pliant Therapeutics and other key companies, straight to your email. Email Address About Pliant TherapeuticsPliant Therapeutics (NASDAQ:PLRX) is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis. Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways. These medicines are investigational and are not approved treatments. Based in South San Francisco, California, Pliant has conducted clinical research in the United States and other countries. Its work is focused on drug discovery and development rather than providing medical products or services directly to patients.View Pliant Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.